^
Association details:
| Biomarker: | TMB-H + PD-L1 overexpression |
|---|---|
| Cancer: | Fibrosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + ifosfamide (Bifunctional alkylating agent) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient
Published date:
03/26/2021
Excerpt:
A 42-year-old male...showed a high-grade myxofibrosarcoma...About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts....Then the patient received 3 cycles of chemotherapy with cisplatin, ifosfamide and epirubicin....a follow-up chest computed tomography (CT) scan (July 1, 2018) depicted enlarged nodules, indicating disease progression...myxofibrosarcoma with no response to conventional therapeutic options, immunotherapy is a promising selection.
DOI:
10.1097/MD.0000000000025262
